28, Jul 2026
New Technogym Checkup measures your physical and cognitive parameters for a targeted training
New Technogym Checkup – the innovative AI-based assessment station – targets your training depending on your physical and functional parameters and, by leveraging artificial intelligence, it obtains the prescription of a precision program tailored to your needs, goals, and conditions.
Scientific studies confirm that health is influenced by only 20-30% by genetics, while the remaining 70-80% depends on epigenetics (lifestyle). There are therefore no magic formulas to achieve Healthness: it requires training that targets muscular strength, cardiovascular endurance, balance, flexibility, and cognitive quality. Physical exercise is a true medicine (Exercise Is Medicine) and Healthness represents a preventative medicine to improve physical performance in the short term and guarantee healthy longevity in the long term.
Thanks to the trillions of data collected in 30 years on the Mywellness Open Platform, today with AI, Technogym is able to offer Healthness as products and services: Technogym Checkup, the new assessment station based on AI is able to analyze psycho-physical and cognitive parameters and automatically calculate Precision Training programs. The new AI-based Biostrength and Biocardio product ranges, connected to the Technogym Ecosystem, allow you to deliver Precision Training Programs automatically thanks to the Technogym App, to track data and adapt the program to progresses.
After logging in with Technogym App, Technogym Checkup will measure your body composition, strength, balance, mobility, and cognitive abilities through precise and reliable tests. The data collected with Technogym Checkup, available within Technogym Ecosystem, will be processed by Technogym AI Coach – Technogym’s AI digital trainer – and transformed into a personalized training protocol, based on real data and always at your fingertips, ensuring a precision training experience and improving your lifestyle from all angles. Thanks to Technogym Ecosystem, you can access your training program anywhere and anytime: at the gym, at home, in a hotel, at work, or with your doctor.
Additionally, Technogym Checkup calculates your Wellness Age, the age mirroring your physical and functional conditions. With this starting point, you can progressively improve thanks to your targeted precision training program while decreasing your Wellness Age, to make you healthier. Thanks to AI, the training program adapts over time to be closer to your goals: superior results faster.
The Sand Stone collection by Technogym offers a renewed aesthetic inspired by nature, combining careful design and advanced materials to differentiate and elevate the design of the most exclusive wellness spaces. Sand Stone’s versatile and cross-cutting aesthetic offering is the only one that enables the creation of wall-to-wall wellness spaces that include products for cardio, strength and functional training in a complete family feeling. This creates a refined environment where design and performance merge into a seamless experience across different lines and products: Technogym Checkup, Artis cardio, Artis strength, Biostrength, up to Personal Tools and Technogym Reform.
Together, these elements create a holistic and exclusive design language made up of warm and welcoming tones that invite everyone to train without intimidation, offering users a unique wellness experience and operators the opportunity to create unique and differentiated spaces.
- 0
- By Neel Achary
28, Jul 2026
Ambuja Cements Records Strong Start to FY27, Advances Capacity Expansion Plans
New Delhi, July 28: Ambuja Cements has begun the financial year 2026–27 with strong operational performance, while continuing to focus on expanding its cement production capacity to 119 million tonnes per annum (MTPA).
The company’s expansion strategy aims to meet rising demand from India’s infrastructure and construction sectors while strengthening operational efficiency and long-term growth.
Ambuja Cements is investing in capacity enhancement, technology upgrades, and sustainable manufacturing practices to improve productivity and support future market requirements.
The company said the expansion plans will help strengthen its position in the cement industry and contribute to India’s ongoing infrastructure development.
With continued focus on growth, efficiency, and sustainability, Ambuja Cements is working towards building a stronger and more competitive business in the coming years.
28, Jul 2026
SBI Life Insurance registers New Business Premium of ₹8,908 crores for the period ended on 30th June, 2026
MUMBAI, India, July 28, 2026 /PRNewswire/ — SBI Life Insurance, one of the leading life insurers in the country registered a New Business Premium of ₹8,908 crores for the period ended on 30th June, 2026 vis-a-vis ₹7,268 crores for the period ended 30th June, 2025. Regular premium has increased by 40% over the period ended on 30th June, 2025.
Establishing a clear focus on protection, SBI Life’s protection new business premium stood at ₹1,958 crores for the period ended 30th June, 2026, marking a growth of 100%. Protection Individual new business premium registered a growth of 22% and stood at ₹202 crores for the period ended 30th June, 2026. Individual New Business Premium stands at ₹5,613 crores with 14% growth over the period ended on 30th June, 2025.
SBI Life’s profit after tax stands at ₹725 crores for the period ended 30th June, 2026 with a growth of 22% over the period ended on 30th June, 2025.
The company’s solvency ratio continues to remain robust at 1.96 as on 30th June, 2026 as against the regulatory requirement of 1.50.
SBI Life’s AUM also continued to grow at 10% to ₹5,24,850 crores as on 30th June, 2026 from ₹4,75,813 crores as on 30th June, 2025, with the debt-equity mix of 60:40. 94% of the debt investments are in AAA and Sovereign instruments.
The company has a diversified distribution network of 3,71,935 trained insurance professionals and wide presence with 1,241 offices across the country, comprising of strong bancassurance channel, agency channel and others comprising of corporate agents, brokers, Point of sale persons (POS), insurance marketing firms, web aggregators and direct business.
Performance for the period ended June 30, 2026
- Private Market leadership in Individual New Business Premium and Individual Rated Premium with market share of 24.9% & 22.2% respectively.
- Annualized Premium Equivalent (APE) stands at ₹ 5,379 crores with growth of 36%
- Total New Business Sum Assured stands at ₹ 8,50,025 crores with 211% growth
- Improvement in 13M & 49M persistency by 61 bps & 68 bps respectively
- Value of New Business (VoNB) stands at ₹ 1,408 crores with growth of 29%
- VoNB Margin stands at 26.2%
- Indian Embedded value (IEV) stands at ₹ 85,293 crores with 15% growth
- Profit After Tax (PAT) stands at ₹ 725 crores with 22% growth
- Robust Solvency ratio of 1.96
- Assets under Management stands at ₹ 5,24,850 crores with 10% growth
Disclaimer
Except for the historical information contained herein, statements in this release which contain words or phrases such as ‘will’, ‘expected to’, etc., and similar expressions or variations of such expressions may constitute ‘forward-looking statements’. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, the actual growth in demand for insurance and other financial products and services in the countries that we operate or where a material number of our customers reside, our ability to successfully implement our strategy, including our use of the Internet and other technology our exploration of merger and acquisition opportunities, our ability to integrate mergers or acquisitions into our operations and manage the risks associated with such acquisitions to achieve our strategic and financial objectives, our growth and expansion in domestic and overseas markets, technological changes, our ability to market new products, the outcome of any legal, tax or regulatory proceedings in India and in other jurisdictions we are or become a party to, the future impact of new accounting standards, our ability to implement our dividend policy, the impact of changes in insurance regulations and other regulatory changes in India and other jurisdictions on us. SBI Life Insurance Company Limited undertakes no obligation to update forward looking statements to reflect events or circumstances after the date thereof.
This release does not constitute an offer of securities.
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/sbi-life-insurance-registers-new-business-premium-of-8-908-crores-for-the-period-ended-on-30th-june-2026–302836348.html
28, Jul 2026
SBI Life Insurance registers New Business Premium of ₹8,908 crores for the period ended on 30th June, 2026
MUMBAI, India, July 28, 2026 /PRNewswire/ — SBI Life Insurance, one of the leading life insurers in the country registered a New Business Premium of ₹8,908 crores for the period ended on 30th June, 2026 vis-a-vis ₹7,268 crores for the period ended 30th June, 2025. Regular premium has increased by 40% over the period ended on 30th June, 2025.
Establishing a clear focus on protection, SBI Life’s protection new business premium stood at ₹1,958 crores for the period ended 30th June, 2026, marking a growth of 100%. Protection Individual new business premium registered a growth of 22% and stood at ₹202 crores for the period ended 30th June, 2026. Individual New Business Premium stands at ₹5,613 crores with 14% growth over the period ended on 30th June, 2025.
SBI Life’s profit after tax stands at ₹725 crores for the period ended 30th June, 2026 with a growth of 22% over the period ended on 30th June, 2025.
The company’s solvency ratio continues to remain robust at 1.96 as on 30th June, 2026 as against the regulatory requirement of 1.50.
SBI Life’s AUM also continued to grow at 10% to ₹5,24,850 crores as on 30th June, 2026 from ₹4,75,813 crores as on 30th June, 2025, with the debt-equity mix of 60:40. 94% of the debt investments are in AAA and Sovereign instruments.
The company has a diversified distribution network of 3,71,935 trained insurance professionals and wide presence with 1,241 offices across the country, comprising of strong bancassurance channel, agency channel and others comprising of corporate agents, brokers, Point of sale persons (POS), insurance marketing firms, web aggregators and direct business.
Performance for the period ended June 30, 2026
- Private Market leadership in Individual New Business Premium and Individual Rated Premium with market share of 24.9% & 22.2% respectively.
- Annualized Premium Equivalent (APE) stands at ₹ 5,379 crores with growth of 36%
- Total New Business Sum Assured stands at ₹ 8,50,025 crores with 211% growth
- Improvement in 13M & 49M persistency by 61 bps & 68 bps respectively
- Value of New Business (VoNB) stands at ₹ 1,408 crores with growth of 29%
- VoNB Margin stands at 26.2%
- Indian Embedded value (IEV) stands at ₹ 85,293 crores with 15% growth
- Profit After Tax (PAT) stands at ₹ 725 crores with 22% growth
- Robust Solvency ratio of 1.96
- Assets under Management stands at ₹ 5,24,850 crores with 10% growth
Disclaimer
Except for the historical information contained herein, statements in this release which contain words or phrases such as ‘will’, ‘expected to’, etc., and similar expressions or variations of such expressions may constitute ‘forward-looking statements’. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, the actual growth in demand for insurance and other financial products and services in the countries that we operate or where a material number of our customers reside, our ability to successfully implement our strategy, including our use of the Internet and other technology our exploration of merger and acquisition opportunities, our ability to integrate mergers or acquisitions into our operations and manage the risks associated with such acquisitions to achieve our strategic and financial objectives, our growth and expansion in domestic and overseas markets, technological changes, our ability to market new products, the outcome of any legal, tax or regulatory proceedings in India and in other jurisdictions we are or become a party to, the future impact of new accounting standards, our ability to implement our dividend policy, the impact of changes in insurance regulations and other regulatory changes in India and other jurisdictions on us. SBI Life Insurance Company Limited undertakes no obligation to update forward looking statements to reflect events or circumstances after the date thereof.
This release does not constitute an offer of securities.
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/sbi-life-insurance-registers-new-business-premium-of-8-908-crores-for-the-period-ended-on-30th-june-2026–302836348.html
28, Jul 2026
SBI Life Insurance registers New Business Premium of ₹8,908 crores for the period ended on 30th June, 2026
MUMBAI, India, July 28, 2026 /PRNewswire/ — SBI Life Insurance, one of the leading life insurers in the country registered a New Business Premium of ₹8,908 crores for the period ended on 30th June, 2026 vis-a-vis ₹7,268 crores for the period ended 30th June, 2025. Regular premium has increased by 40% over the period ended on 30th June, 2025.
Establishing a clear focus on protection, SBI Life’s protection new business premium stood at ₹1,958 crores for the period ended 30th June, 2026, marking a growth of 100%. Protection Individual new business premium registered a growth of 22% and stood at ₹202 crores for the period ended 30th June, 2026. Individual New Business Premium stands at ₹5,613 crores with 14% growth over the period ended on 30th June, 2025.
SBI Life’s profit after tax stands at ₹725 crores for the period ended 30th June, 2026 with a growth of 22% over the period ended on 30th June, 2025.
The company’s solvency ratio continues to remain robust at 1.96 as on 30th June, 2026 as against the regulatory requirement of 1.50.
SBI Life’s AUM also continued to grow at 10% to ₹5,24,850 crores as on 30th June, 2026 from ₹4,75,813 crores as on 30th June, 2025, with the debt-equity mix of 60:40. 94% of the debt investments are in AAA and Sovereign instruments.
The company has a diversified distribution network of 3,71,935 trained insurance professionals and wide presence with 1,241 offices across the country, comprising of strong bancassurance channel, agency channel and others comprising of corporate agents, brokers, Point of sale persons (POS), insurance marketing firms, web aggregators and direct business.
Performance for the period ended June 30, 2026
- Private Market leadership in Individual New Business Premium and Individual Rated Premium with market share of 24.9% & 22.2% respectively.
- Annualized Premium Equivalent (APE) stands at ₹ 5,379 crores with growth of 36%
- Total New Business Sum Assured stands at ₹ 8,50,025 crores with 211% growth
- Improvement in 13M & 49M persistency by 61 bps & 68 bps respectively
- Value of New Business (VoNB) stands at ₹ 1,408 crores with growth of 29%
- VoNB Margin stands at 26.2%
- Indian Embedded value (IEV) stands at ₹ 85,293 crores with 15% growth
- Profit After Tax (PAT) stands at ₹ 725 crores with 22% growth
- Robust Solvency ratio of 1.96
- Assets under Management stands at ₹ 5,24,850 crores with 10% growth
Disclaimer
Except for the historical information contained herein, statements in this release which contain words or phrases such as ‘will’, ‘expected to’, etc., and similar expressions or variations of such expressions may constitute ‘forward-looking statements’. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, the actual growth in demand for insurance and other financial products and services in the countries that we operate or where a material number of our customers reside, our ability to successfully implement our strategy, including our use of the Internet and other technology our exploration of merger and acquisition opportunities, our ability to integrate mergers or acquisitions into our operations and manage the risks associated with such acquisitions to achieve our strategic and financial objectives, our growth and expansion in domestic and overseas markets, technological changes, our ability to market new products, the outcome of any legal, tax or regulatory proceedings in India and in other jurisdictions we are or become a party to, the future impact of new accounting standards, our ability to implement our dividend policy, the impact of changes in insurance regulations and other regulatory changes in India and other jurisdictions on us. SBI Life Insurance Company Limited undertakes no obligation to update forward looking statements to reflect events or circumstances after the date thereof.
This release does not constitute an offer of securities.
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/sbi-life-insurance-registers-new-business-premium-of-8-908-crores-for-the-period-ended-on-30th-june-2026–302836348.html
28, Jul 2026
New Milestone for Mysuru as Viveka Smaraka Set for Inauguration
Mysuru, July 28: Mysuru is set to witness the inauguration of Viveka Smaraka on August 1, marking the addition of a new landmark dedicated to inspiring people through the values of knowledge, service, and cultural heritage.
Prime Minister Narendra Modi will inaugurate the memorial, which is expected to become a place of learning and reflection while showcasing India’s rich traditions and inspiring legacy.
The initiative aims to preserve and promote values associated with social service, spirituality, and nation-building, providing visitors with an opportunity to connect with India’s cultural roots.
Officials said the memorial will further enhance Mysuru’s identity as a major cultural destination and attract visitors interested in heritage and history.
The inauguration is expected to bring together dignitaries, officials, and citizens, highlighting the importance of preserving institutions that inspire future generations.
The Viveka Smaraka is set to become another significant addition to Mysuru’s heritage landscape, encouraging awareness, learning, and appreciation of India’s cultural values.
28, Jul 2026
Chandigarh University Researchers Develop an Economical Device for Accurate Drug Absorption Studies; to Help in Reducing Cost of Medicines by 40%
Chandigarh University researchers get patent for an energy-efficient, economical device for accurate drug absorption studies
CHANDIGARH, India, July 28, 2026 /PRNewswire/ — A team of researchers at Chandigarh University has developed an innovative laboratory device that could significantly improve the way oral medicines are tested during development, enabling more accurate, reliable and cost-effective drug absorption studies that can ultimately support the development of safer and more effective medicines. By addressing several long-standing limitations in conventional drug absorption equipment, the innovation enables researchers to generate more dependable experimental data while reducing the likelihood of failed studies, repeated experiments and unnecessary research costs. The improved version of the apparatus also reduces the size and complexity of the conventional equipment, resulting in a 40 per cent reduction in operational costs and making a low-cost version of the device available for pharmaceutical research and routine laboratory use.
Recognizing the novelty and practical significance of the innovation, the Indian Patent Office has granted the Chandigarh University researchers a patent for their invention titled ‘Improved Oral Drug Absorption Study Cell’. The innovation, developed by Chandigarh University researchers, Prof. (Dr.) S.S. Sehgal and Prof. (Dr.) Manish Goswami (former professor at University Institute of Pharmaceutical Sciences), Chandigarh University, has been granted a patent by the Indian Patent Office for its novel design. The patented device introduces engineering improvements that overcome several limitations of the conventional drug absorption apparatus while remaining simple to manufacture, economical to operate and suitable for routine laboratory use.
The reliable drug absorption studies form the foundation of oral medicine development, helping scientists determine whether a medicine administered orally can efficiently cross the intestinal barrier and enter the bloodstream before it progresses to advanced stages of research. More accurate laboratory data allows researchers to optimise formulations much earlier in the development cycle, reducing uncertainty before medicines move to expensive pre-clinical and clinical evaluation while strengthening confidence in pharmaceutical research.
Sharing details and significance of the innovation, Prof. (Dr.) S.S. Sehgal said, “Drug absorption studies are among the most important stages in oral drug development because they help scientists understand how efficiently a medicine is likely to be absorbed before it progresses to advanced stages of research. The conventional drug absorption equipment offer very limited space, forcing researchers to fold the everted intestinal tissue inside the chamber. This places unnecessary stress on the tissue, affects its natural positioning and can result in variability into the drug experimental observations. In many cases, tissue damage or improper placement can even result in experimental failure that forces researchers to repeat the study and increase both development time and research costs.”
Prof. Sehgal added, “Instead of altering the testing methodology, we redesigned the apparatus to address the limitations of conventional systems. By introducing an extended side arm, our equipment allows the tissue to remain in a natural U-shaped position helping in proper drug absorption to occur under consistent conditions. Along with improved temperature uniformity, better mixing of the drug solution and greater operational stability, the redesigned apparatus helps generate more accurate and reproducible data that can improve the evaluation of oral drug formulations.”
Highlighting the broader impact of the invention, Prof. (Dr.) Manish Goswami said, “Scientific progress is often driven by improving the tools researchers use every day. Even relatively small improvements in laboratory equipment can have a significant impact on the quality of research data. By making drug absorption studies more reliable and easier to perform, this innovation can support pharmaceutical scientists in developing better oral formulations and ultimately contribute to medicines that offer greater therapeutic effectiveness for patients.”
Elaborating on the improvements, Dr. Manish Goswami said, “Our objective was to improve the reliability of the experiment through a simple yet effective engineering solution. One of the biggest advantages of this innovation is that it minimizes variations during sample collection, making drug absorption studies more reliable and consistent. The device features a compact design built using laboratory-grade materials such as borosilicate and Teflon-coated glass to ensure durability and precision. At the same time, its optimized architecture reduces the overall size of the apparatus, simplifies fabrication and handling, and lowers operational costs by 40 per cent, making it an economical solution for pharmaceutical research. These improvements create more consistent and reproducible experimental conditions, enabling researchers to generate higher-quality data without adding complexity to the procedure.”
The innovation is expected to benefit through its application in pharmaceutical industry, drug discovery and development sector, pharmaceutical R&D centres, Contract Research Organizations (CROs), Clinical Research Organizations (CROs), universities and pharmacy colleges, government research laboratories and regulatory testing laboratories where drug absorption studies are routinely carried out for formulation development, pre-clinical research and evaluation of oral medicines.
Apart from improving the experimental accuracy, the redesigned apparatus also reduces operational complexity by eliminating the need for extra heating arrangements. Its simplified design lowers energy requirements, improves laboratory efficiency and reduces overall operating costs, making it suitable for routine use across pharmaceutical laboratories, academic institutions and research organisations.
With oral medicines accounting for the majority of pharmaceutical formulations used worldwide, improvements in early-stage drug absorption studies can strengthen the entire drug development process. By enabling more reliable laboratory testing while reducing time, cost and experimental variability, Chandigarh University’s patented innovation has the potential to support faster formulation optimisation, improve pharmaceutical research and contribute to the development of safer, more effective oral medicines for patients across the globe.
About Chandigarh University
Chandigarh University is a NAAC A+ Grade University and QS World Ranked University. This autonomous educational institution is approved by UGC and is located near Chandigarh in the state of Punjab. It is the youngest university in India and the only private university in Punjab to be honoured with A+ Grade by NAAC (National Assessment and Accreditation Council). CU offers more than 109 UG and PG programs in the field of engineering, management, pharmacy, law, architecture, journalism, animation, hotel management, commerce, and others. It has been awarded as The University with Best Placements by WCRC.
Website address: https://www.cuchd.in/
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/chandigarh-university-researchers-develop-an-economical-device-for-accurate-drug-absorption-studies-to-help-in-reducing-cost-of-medicines-by-40-302836315.html
28, Jul 2026
Flipster Secures VARA Full Operational Exchange License, Advancing Regulated Crypto Services in the UAE
DUBAI, UAE, July 28, 2026 /PRNewswire/ — Flipster, a global cryptocurrency trading platform, has secured a full operational Exchange license (License No. VL/26/07/002) from Dubai’s Virtual Assets Regulatory Authority (VARA) under Flipster FZE. This milestone enables Flipster to officially launch regulated virtual asset services in the region and marks a significant step in its global expansion strategy.
With this license, Flipster FZE is authorized to onboard customers in the UAE, with plans to gradually expand access to a broader global user base. Flipster offers access to real world asset perpetuals in supported jurisdictions, giving users trading exposure to both digital and traditional asset classes. The initial offering will focus on spot trading, forming the foundation of Flipster’s regulated product suite.
This approval marks Flipster’s transition from regulatory readiness and in-principle approval to full operational capability under VARA’s framework, one of the most comprehensive and globally recognized regulatory regimes for digital assets.
Operating under VARA’s framework allows Flipster to provide a more secure and transparent trading environment, supported by robust standards for custody, governance, and compliance. This reinforces the platform’s commitment to safeguarding users while providing reliable access to digital assets.
And it also reflects Flipster’s commitment to meeting the highest standards in global finance. Flipster believes regulation is essential to building long-term trust, and VARA sets a strong benchmark for balancing innovation with investor protection.
Flipster first announced its entry into the Middle East in May 2025 with the appointment of Benjamin Grolimund as General Manager of Flipster FZE. Securing the full operational license marks the next phase of this expansion, as the company moves from market entry to delivering regulated services in one of the world’s most advanced digital asset ecosystems.
About Flipster
Flipster is a leading cryptocurrency trading platform, founded in 2023. It is designed by traders, for traders. With deep liquidity, industry-leading leverage, and wide coverage across global markets, Flipster is built for every trading style and gives traders the flexibility to seize opportunities wherever they emerge. Flipster offers access to real world asset perpetuals in supported jurisdictions, giving users trading exposure to both digital and traditional asset classes from a single platform. Learn more at flipster.io or follow X.
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/flipster-secures-vara-full-operational-exchange-license-advancing-regulated-crypto-services-in-the-uae-302836322.html
28, Jul 2026
TRAI Data Shows Strong Growth in India’s Digital Connectivity
New Delhi, July 28: India’s digital connectivity continued to strengthen in June, with the country’s total telecom subscriber base rising to 1.35 billion, while broadband subscribers crossed 1.08 billion, according to the latest data released by the Telecom Regulatory Authority of India (TRAI).
The increase reflects the continued expansion of telecom services and internet access across the country, supported by growing smartphone adoption, improved network infrastructure, and rising demand for digital services.
TRAI said the steady growth in subscriber numbers highlights India’s rapid progress in expanding communication networks and improving internet accessibility in both urban and rural areas.
Industry experts noted that the expanding telecom and broadband ecosystem is expected to accelerate digital inclusion, support businesses, strengthen online education and healthcare services, and drive the country’s digital economy.
The latest figures also underline the telecom sector’s growing role in enabling innovation, improving connectivity, and supporting India’s vision of a technology-driven and digitally empowered nation.
28, Jul 2026
Indian Railways Sanctions INR 163 Crore Project to Modernise Nanded Division
New Delhi, July 28: Indian Railways has approved a ₹163 crore infrastructure project to upgrade the electric traction system in the Nanded division, marking a significant step towards improving rail operations and network efficiency.
The project will modernise the division’s electric traction infrastructure, helping enhance train movement, improve operational reliability, and strengthen the capacity of the railway network.
Railway officials said the upgrade is expected to support faster and more efficient passenger and freight services while improving energy efficiency and reducing maintenance requirements.
The investment is part of Indian Railways’ broader modernisation drive to build a safer, smarter, and more sustainable rail network across the country.
The project is also expected to improve regional connectivity, strengthen logistics, and support economic activity by enhancing the overall performance of the railway system.
The approval reflects the government’s continued focus on expanding world-class railway infrastructure to meet India’s growing transportation and freight requirements.
